The Future of Drug Trials - Interview

Posted:

September 2006

BBC journalist Graham Easton investigates the future of drug trials following the events of trial TGN1412.The BBC interviewer talks to Professor Gordon Duff (Commission on Human Medicines), Professor Andre Mclean (Imperial College London), Dr Jörg Täubel (Richmond Pharmacology), Professor Terry Hamblin (University of Southampton), Dr Ganesh Suntharalingam (Northwick Park Hospital), Professor Deborah Saltman (BioMedical Central), Dr Elaine Godfrey (MHRA), and Dr Mark Lewis (Strategic Health Authority), to get their opinion leading analysis of the event and the future of drug trials, covering:

What can be learnt and changed from the incident?
Should all first in man trials be conducted in a Hospital setting?
Regulatory issues

Click here to read the transcript

Back to news

More about us Adaptive Phase I & IIa Bridging Studies TQT Studies Patient Recruitment

Meet the experts

Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.

Latest Publications

View our latest peer-reviewed publications from a selection of our clinical trials.

Latest Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020

Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.

View event

COVID-19 – External Monitoring Guidelines

July 1, 2020

Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.

First transdermal patch to treat schizophrenia hits market

March 18, 2020

The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful

Statement: COVID-19

March 23, 2020

Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.